Biotechnology Parkof The Siberian Science Town KOLTSOVO

Novosibirsk2013

Preconditions of a cluster’s development

• Novosibirsk region is located in the heart of Russia. At the crossing of major transport routes connecting Europe and Asia which contributed to the concentration of population, industrial enterprises, scientific and education institutions, infrastructure at its territory in a record-breaking time.

• The modern sectors of economy such as telecommunications, information technologies, trade, banking and financial services have formed there rapidly in recent years.

• The unique concentration of scientific and educational institutions and innovative companies, diversified economy, business development and social infrastructure determine the main directions of the Novosibirsk region development

• The economic policy of the government of the Novosibirsk region is aimed at stimulating investment activity primarily focused on the knowledge-intensive and high-tech production.

2

Scientific center• Novosibirsk is one of the leading Russian regions on the

level of development of medicine and skill level of medical personnel

• The Novosibirsk region has already adopted and implemented the system of human resources training required for development of the biopharmaceutical industry.

• The following institutions and organizations work in the Novosibirsk region:

o Siberian branch of Russian Academy of Scienceo Siberian branch of Russian Academy of Medical Scienceo Siberian branch of Russian Academy of AgriculturalScienceo State Research Center of Virology and Biotechnology

VECTORo More than 60 scientific and research, decignengineering and

design institutes.o More than 100 large and 1 500 small business related to

technology-innovative activities.

3

Biotechnopark KOLTSOVO

Cluster’s tasks:• to promote the production of

innovate drugs and substances• to increas the production of high-

quality affordable drugs – generic drugs and dietary supplements

• to prevent the threat to the national security of Russia

The purpose of Biotechnopark establishment:

• to attract residents – investors into the production of the final forms of the pharmaceutical and biotechnological products

• to attract the enterprises which are able to provide the localization of the product production cycle

4

The establishment of Biotechnopark of the Novosibirsk region is a part of formation and development of innovate territorial cluster “Biopharmaceutical Cluster of the Novosibirsk region”

The total investments for the establishment of Biotechnopark constituted EUR 11.4 million:

•EUR 5 million - from the regional budget •More than EUR 500 thousand - from the municipal budget •About EUR 5.9 million from the funds of private investors.

.

5

Investments and territory

Total planned area: about 114 hectares.Two production platforms -14 and 100 hectares.

Development of infrastructure of the platform №1 allows disposing:• research and production complex for production of

Trombovazim, unique materials for the production of biologically active drugs of the next generation and clinical nutrition,

• complex of medical products sterilization, manufacture and modification of pharmaceutical substances with the help of radiation techniques,

• other companies - residents.

The projecting of Center of Multiple Access for biopharmaceutical companies is nearing completion at the same platform.

Development of the platform № 2: approximately two times increases the infrastructural capacity of Koltsovo for placement of industrial biotechnological and pharmaceutical facilities (by 100% compared to the current level) Ensures the effective placement of innovative industries and businesses - large complex for deep grain processing, plant for antibiotics and antioxidants production, plant for production of biochips and other industries.

Prospects of a cluster’s

development

• The Russian pharmaceutical market will grow with the rates, advancing world average growth rates

• The accelerated development of the enterprises of pharmaceutical branch of the region till 2016, in 2 times exceeding expected market average growth rates in branch should become the purpose of carried-out actions within a created cluster

• For pharmaceutical branch of the Russian Federation expected market average growth rates in the long term are 12 -15 %. For the enterprises – cluster’s participants target indicators are established at a level of 25 % of annual growth in the long term till 2016-2017

6

20092010

20112012

20132014

20152016

 0 2000 000 4000 000 6000 000 8000 000 10000 000 12000 000 14000 000 16000 000 18000 000

Main types of production in a cluster

Revenue of the cluster’s enterprises for the last 3 years

and a forecast for the next years, one thousand rub.

• The prolonged and immobilized forms of medicines• Mathematical methods of forecasting and modeling, database

(bioinformation technologies)• New drugs, medicine forms and delivery systems of active

ingredients, including protected by the patent• Innovative medicines and technologies• Equipment for medicine and biotechnology• Diagnostic aids (test systems)• Unique vaccines

Main actions for realization of target reference points

• In the sphere of production infrastructure:

1. address support to the enterprises–cluster’s participants

2. purposeful development of industrial platforms, production and social infrastructures in interests of resident investors

• In the sphere of researches, development and innovations:

1. creation of conditions for development of competitive researches and development sectors

2. complex development of the innovative infrastructure providing technological possibility of innovation introduction

• In the higher education sphere:

1.ensuring innovative nature of education, formation of innovative thinking

2. participation of univercities in target preparation of demanded experts

8

It is planned:

Not less than 55 innovative projects by 2015 About two thousand high-tech workplaces

First resident

The Novosibirsk group of companies SCIENTIFIC FUTURE MANAGEMENT has become first major Russian resident of Biotechnopark with investments of more than RUB 2 billion which now finishes the release of the drug TROMOVAZIM at this industrial platform with the capacity to 1.5 million units per year.

9

TROMBOVAZIM is a fundamentally new drug with a strong thrombolytic and anti-inflammatory action which is produced in a capsules and injections. It is used in the treatment of chronic venous insufficiency. TROMBOVAZIM increases the fibrinolytic activity of blood providing direct fibrinolytic action. The drug has a trombolytic effect which mechanism is connected with the direct destruction of fibrin forming the basic molecular skeleton of thrombus

THANKS FOR YOUR ATTANTION!

10